logo

Lexicon Pharmaceuticals Inc. (LXRX)



Trade LXRX now with
  Date
  Headline
4/27/2020 7:19:21 AM Lexicon Q1 Revenues Decrease To $8.0 Mln From $9.2 Mln Last Year
3/12/2020 7:23:19 AM Lexicon Q4 Loss $51.1 Mln Or $0.48/Shr Vs Loss $16.8 Mln Or $0.16/Shr Year-ago
12/20/2019 7:07:28 AM Lexicon Pharma Topline Phase 3 Data For Sotagliflozin In Type 2 Diabetes Meets End Points
12/5/2019 7:14:16 AM Lexicon Announces Positive Topline Data From Phase 1 Study Of LX9211
12/2/2019 7:21:58 AM Lexicon Pharma Gets Formal Dispute Resolution Request Decision From FDA’s Office Of New Drugs For Sotagliflozin
9/10/2019 4:06:28 PM Lexicon Pharmaceuticals Announces Termination Of Alliance And Settlement With Sanofi
8/1/2019 10:10:16 AM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $17 Down From $35 Price Target
6/11/2019 12:57:20 PM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $35 Price Target
5/2/2019 8:56:18 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) FY20 Rev. Estimate To 98.2 M From 98.3 M
5/2/2019 8:56:06 AM Wedbush Is Lowering Lexicon Pharmaceuticals Inc. (LXRX) FY19 Rev. Estimate To 63.8 M From 71.0 M
5/2/2019 8:55:49 AM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) Q4 19 Rev. Estimate To 19.5 M From 19.3 M
5/2/2019 8:55:18 AM Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) FY20 Estimate To -1.23 From -1.60